BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36048524)

  • 1. Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.
    Deng J; Paulus A; Fang DD; Manna A; Wang G; Wang H; Zhu S; Chen J; Min P; Yin Y; Dutta N; Halder N; Ciccio G; Copland JA; Miller J; Han B; Bai L; Liu L; Wang M; McEachern D; Przybranowski S; Yang CY; Stuckey JA; Wu D; Li C; Ryan J; Letai A; Ailawadhi S; Yang D; Wang S; Chanan-Khan A; Zhai Y
    Clin Cancer Res; 2022 Dec; 28(24):5455-5468. PubMed ID: 36048524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
    Ailawadhi S; Chen Z; Huang B; Paulus A; Collins MC; Fu LT; Li M; Ahmad M; Men L; Wang H; Davids MS; Liang E; Mekala DJ; He Z; Lasica M; Yannakou CK; Parrondo R; Glass L; Yang D; Chanan-Khan A; Zhai Y
    Clin Cancer Res; 2023 Jul; 29(13):2385-2393. PubMed ID: 37074726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
    Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
    Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
    Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
    J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.
    Sun YL; Jiang WQ; Luo QY; Yang DJ; Cai YC; Huang HQ; Sun J
    BMC Cancer; 2019 Dec; 20(1):1. PubMed ID: 31892356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
    Jane EP; Premkumar DR; Morales A; Foster KA; Pollack IF
    J Pharmacol Exp Ther; 2014 Jul; 350(1):22-35. PubMed ID: 24741074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells.
    Wang J; Yang D; Luo Q; Qiu M; Zhang L; Li B; Chen H; Yi H; Yan X; Li S; Sun J
    Int J Oncol; 2017 Aug; 51(2):563-572. PubMed ID: 28586007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases.
    Holinger EP; Chittenden T; Lutz RJ
    J Biol Chem; 1999 May; 274(19):13298-304. PubMed ID: 10224090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Okumura K; Sinicrope FA
    Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.
    Tse C; Shoemaker AR; Adickes J; Anderson MG; Chen J; Jin S; Johnson EF; Marsh KC; Mitten MJ; Nimmer P; Roberts L; Tahir SK; Xiao Y; Yang X; Zhang H; Fesik S; Rosenberg SH; Elmore SW
    Cancer Res; 2008 May; 68(9):3421-8. PubMed ID: 18451170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
    Turner BC; Eves T; Refaeli Y
    DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation.
    Vela L; Gonzalo O; Naval J; Marzo I
    J Biol Chem; 2013 Feb; 288(7):4935-46. PubMed ID: 23283967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
    Valentin R; Grabow S; Davids MS
    Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1.
    Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G
    Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.